Association between statin therapy and tendon rupture: A case-control study

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 5, 2009, Pages 401-404

  Beri, Abhimanyu ^a,c   Dwamena, Francesca C ^a   Dwamena, Ben A ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c B301 Clinical Center   (United States)

Author keywords

Case control; Hydroxymethylglutaryl CoA reductase inhibitor; Statin; Tendon rupture

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID;

ADULT; AGE DISTRIBUTION; ARTICLE; ATTRIBUTABLE RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK FACTOR; SEX DIFFERENCE; TENDON RUPTURE;

CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RUPTURE, SPONTANEOUS; SEX FACTORS; TENDON INJURIES;

EID: 67650869724     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a0ce8b     Document Type: Article

References (27)

1. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients. A hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45.
2. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358:1819-1828. (Pubitemid 351581194)
3. Gaist D, Garcia-Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy. Epidemiology. 2001;12:565-569.
4. Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 2007;100:152-153.
5. Chazerain P, Hayem G, Hamza S, et al. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine. 2001;68:430-433. (Pubitemid 32988530)
6. Falip S, Battlo M, Peyriere H, et al. Statin induced tendinopathies: analysis of 37 cases in the French Pharmacovigilance database. Fundam Clin Pharmacol. 2005;19:231. Abstract.
7. Parkinson J, Wolfe SM. Public Citizen Petitions the FDA to include a Black Box on Fluoroquinolore Antibiotics. Available at: http://www. citizen.org/publications/release.cfm?ID=7453. Accessed June 18, 2008.
8. Marie I, Delafenêtre H, Massy N, et al. Network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum. 2008;59:367-372.
9. Lipitor Prescribing Information. Available at: http://www.lipitor.com/ content/LipitorPI.pdf. Accessed July 16, 2008.
10. Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15:784-792. (Pubitemid 44762709)
11. Jones N, Kjellstrand CM. Spontaneous tendon rupture in patients on chronic dialysis. Am J Kidney Dis. 1996;28:861-866. (Pubitemid 26412082)
12. Shah MK. Simultaneous bilateral quadriceps tendon rupture in renal patients. Clin Nephrol. 2002;58:118-121. (Pubitemid 34855091)
13. Bhole R, Flynn J, Marbury T. Quadriceps tendon ruptures in uremia. Clin Orthop Relat Res. 1985;195:200-206.
14. Shah MK. Simultaneous bilateral rupture of quadriceps tendons: analysis of risk factors and associations. South Med J. 2002;95:860-866.
15. Mounasamy V, Chadderdon RC, McDaniel C, et al. Bilateral synchronous quadriceps tendon rupture: a case report. Eur J Orthop Surg Traumatol. 2008;18:63-67.
16. Schlesselman JJ. Case Control Studies: Design, Conduct, Analysis. New York: Oxford University Press; 1982.
17. Wiley MH, Howton MM, Siperstein MD. Sex differences in the sterol and nonsterol metabolism of mevalonate. J Biol Chem. 1979;254:837-842.
18. Brady PF, Scofield RF, Mann S, et al. Effects of estrogen and testosterone on the metabolism of mevalonate by the shunt pathway. J Lipid Res. 1983;24:1168-1175. (Pubitemid 14236568)
19. Merola AJ, Arnold A. Estrone inhibition of cholesterol biosynthesis at the mevalonic acid stage. Science. 1964;144:301-302.
20. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(Suppl 1):SII18-SII26.
21. Turner NA, O'Regan DJ, Ball SG, et al. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005;19:804-806.
22. Clegg PD, Strassburg S, Smith RK. Cell phenotypic variation in normal and damaged tendons. Int J Exp Path. 2007;88:227-235. (Pubitemid 47256310)
23. Riley G. Symposium: tendon and ligament remodelling and regeneration. Int J Exp Path. 2007;88:215-216.
24. Magnusson SP, Hansen M, Langberg H, et al. The adaptability of tendon to loading differs in men and women. Int J Exp Path. 2007;88:237-240. (Pubitemid 47256311)
25. Jones BH, Bovee MW, Harris JM III, et al. Intrinsic risk factors for exercise-related injuries among male and female army trainees. Am J Sports Med. 1993;21:705-710.
26. Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin induced myopathy. Arch Intern Med. 2005;165:2671-2676.
27. Rosenson R. Current overview of statin-induced myopathy. Am J Med. 2005;116:408-416.